163 related articles for article (PubMed ID: 3416575)
1. Occurrence of haemorrhagic and thrombotic events in myeloproliferative disorders: a retrospective study of 108 patients.
Grossi A; Rosseti S; Vannucchi AM; Rafanelli D; Ferrini PR
Clin Lab Haematol; 1988; 10(2):167-75. PubMed ID: 3416575
[TBL] [Abstract][Full Text] [Related]
2. Thrombohaemorrhagic complications in 101 cases of myeloproliferative disorders: relationship to platelet number and function.
Barbui T; Cortelazzo S; Viero P; Bassan R; Dini E; Semeraro N
Eur J Cancer Clin Oncol; 1983 Nov; 19(11):1593-9. PubMed ID: 6580171
[TBL] [Abstract][Full Text] [Related]
3. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. A retrospective analysis of 260 patients.
Wehmeier A; Daum I; Jamin H; Schneider W
Ann Hematol; 1991 Aug; 63(2):101-6. PubMed ID: 1912029
[TBL] [Abstract][Full Text] [Related]
4. Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden.
Lim Y; Lee JO; Kim SH; Kim JW; Kim YJ; Lee KW; Lee JS; Bang SM
Thromb Res; 2015 May; 135(5):846-51. PubMed ID: 25743883
[TBL] [Abstract][Full Text] [Related]
5. [Significance of the JAK2V617F mutation in patients with chronic myeloproliferative neoplasia].
Iványi JL; Marton E; Plander M
Orv Hetil; 2011 Nov; 152(45):1795-803. PubMed ID: 22011365
[TBL] [Abstract][Full Text] [Related]
6. [Association of hemorrhagic and thrombotic phenomena in myeloproliferative syndromes].
Meschengieser SS; Woods AI; Schattner MA; Lazzari MA
Medicina (B Aires); 1981; 41 Suppl():267-73. PubMed ID: 6954340
[No Abstract] [Full Text] [Related]
7. Analysis of risk factors predicting thrombotic and/or haemorrhagic complications in 306 patients with essential thrombocythemia.
Radaelli F; Colombi M; Calori R; Zilioli VR; Bramanti S; Iurlo A; Zanella A
Hematol Oncol; 2007 Sep; 25(3):115-20. PubMed ID: 17464935
[TBL] [Abstract][Full Text] [Related]
8. Erythromelalgia--a thrombotic complication in chronic myeloproliferative disorders.
Tarach JS; Nowicka-Tarach BM; Matuszek B; Nowakowski A
Med Sci Monit; 2000; 6(1):204-8. PubMed ID: 11208311
[TBL] [Abstract][Full Text] [Related]
9. The myeloproliferative disorders. An historical appraisal and personal experiences.
Michiels JJ
Leuk Lymphoma; 1996 Sep; 22 Suppl 1():1-14. PubMed ID: 8951768
[TBL] [Abstract][Full Text] [Related]
10. Heparin-induced thrombocytopenia in patients with Philadelphia-negative myeloproliferative disorders and unusual splanchnic or cerebral vein thrombosis.
Randi ML; Tezza F; Scapin M; Duner E; Scarparo P; Scandellari R; Fabris F
Acta Haematol; 2010; 123(3):140-5. PubMed ID: 20134155
[TBL] [Abstract][Full Text] [Related]
11. High prevalence of hyperhomocysteinemia due to marginal deficiency of cobalamin or folate in chronic myeloproliferative disorders.
Faurschou M; Nielsen OJ; Jensen MK; Hasselbalch HC
Am J Hematol; 2000 Oct; 65(2):136-40. PubMed ID: 10996831
[TBL] [Abstract][Full Text] [Related]
12. Thrombosis and bleeding in polycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention.
Landolfi R; Cipriani MC; Novarese L
Best Pract Res Clin Haematol; 2006; 19(3):617-33. PubMed ID: 16781491
[TBL] [Abstract][Full Text] [Related]
13. Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies.
Landolfi R; Di Gennaro L; Novarese L; Patrono C
Semin Thromb Hemost; 2006 Apr; 32(3):251-9. PubMed ID: 16673279
[TBL] [Abstract][Full Text] [Related]
14. The paradox of platelet activation and impaired function: platelet-von Willebrand factor interactions, and the etiology of thrombotic and hemorrhagic manifestations in essential thrombocythemia and polycythemia vera.
Michiels JJ; Berneman Z; Schroyens W; Finazzi G; Budde U; van Vliet HH
Semin Thromb Hemost; 2006 Sep; 32(6):589-604. PubMed ID: 16977569
[TBL] [Abstract][Full Text] [Related]
15. Life-threatening thrombotic and haemorrhagic problems associated with silent myeloproliferative disorders.
Vadher BD; Machin SJ; Patterson KG; Sukhu C; Walker H
Br J Haematol; 1993 Sep; 85(1):213-6. PubMed ID: 8251397
[TBL] [Abstract][Full Text] [Related]
16. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Sankar K; Stein BL; Rampal RK
Cancer Treat Res; 2019; 179():159-178. PubMed ID: 31317487
[TBL] [Abstract][Full Text] [Related]
17. [Thrombosis in myeloproliferative neoplasms].
Asakura H
Rinsho Ketsueki; 2018; 59(8):1034-1041. PubMed ID: 30185703
[TBL] [Abstract][Full Text] [Related]
18. Hemorrhagic and thrombotic complications in patients with myeloproliferative diseases.
Vignal CV; Lourenço DM; Noguti MA; Chauffaille Mde L; Kerbauy J
Sao Paulo Med J; 1997; 115(6):1575-9. PubMed ID: 9640794
[TBL] [Abstract][Full Text] [Related]
19. Clinical and laboratory features, pathobiology of platelet-mediated thrombosis and bleeding complications, and the molecular etiology of essential thrombocythemia and polycythemia vera: therapeutic implications.
Michiels JJ; Berneman Z; Van Bockstaele D; van der Planken M; De Raeve H; Schroyens W
Semin Thromb Hemost; 2006 Apr; 32(3):174-207. PubMed ID: 16673274
[TBL] [Abstract][Full Text] [Related]
20. Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: incidence, risk factors, and effect of treatments.
De Stefano V; Za T; Rossi E; Vannucchi AM; Ruggeri M; Elli E; Micò C; Tieghi A; Cacciola RR; Santoro C; Gerli G; Vianelli N; Guglielmelli P; Pieri L; Scognamiglio F; Rodeghiero F; Pogliani EM; Finazzi G; Gugliotta L; Marchioli R; Leone G; Barbui T;
Haematologica; 2008 Mar; 93(3):372-80. PubMed ID: 18268279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
